ClinicalTrials.gg
CompletedNCT00127127Updated Sep 13, 2022Results posted

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

A Phase 1 interventional study of vorinostat in Tumors, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in participants with solid tumors.

02

Conditions studied

  • Tumors

Browse trials for

Keywords

  • Solid tumors
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 18 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with or cytologically diagnosed solid tumor; no standard therapy available or participant has failed to respond to standard therapy

Exclusion criteria

Exclusion Criteria:

  • Participants with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks; previous treatment is 5 or more chemotherapeutic regimens.
  • Any uncontrolled concomitant illness
  • Are pregnant or breast-feeding
  • Serious drug or food allergy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Vorinostat 100 mg

    During Cycle 1, participants receive a single oral dose of vorinostat 100 mg on Day 1 in a fasted state, Day 3 in a fed state, and Day 19 in a fed state. On Days 5-18, participants receive vorinostat 100 mg twice daily, in the morning and evening. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)

    Drug: vorinostat

  • Experimental
    Vorinostat 200 mg

    During Cycle 1, participants receive a single oral dose of vorinostat 200 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive vorinostat 200 mg twice daily, in the morning and evening. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)

    Drug: vorinostat

  • Experimental
    Vorinostat 400 mg

    During Cycle 1, participants receive a single oral dose of vorinostat 400 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive a single oral dose of vorinostat 400 mg once-daily in the morning. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)

    Drug: vorinostat

  • Experimental
    Vorinostat 500 mg

    During Cycle 1, participants receive a single oral dose of vorinostat 500 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive a single oral dose of vorinostat 500 mg once-daily in the morning. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy on the Cycle 2 and subsequent cycles.(Each cycle will be 26 days.)

    Drug: vorinostat

Interventions

  • vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration

    Also known as: MK-0683, L-001079038, suberoylanilide hydroxamic acid (SAHA)

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced One or More Adverse Events

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 4 years

  2. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 4 years

  3. Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1

    A DLT was defined as an event considered to be related to study treatment and included: 1) Grade 4 neutropenia refractory to treatments persisting more than 5 days; 2) Grade 3 or more severe neutropenic fever; 3) Grade 3 thrombocytopenia requiring blood transfusions or Grade 4 thrombocytopenia; 4) Grade 4 hemoglobin decrease; 5) Grade 3 or more severe non-hematological toxicities other than anorexia, nausea/vomiting, and fatigue. (For the diarrhea, it was defined as not to use the frequency for the grading. For the alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]), it was defined as the case of over 300 IU/L; 6) Grade 3 or more severe anorexia, nausea/vomiting, and fatigue refractory to treatments; and 7) compliance of the study drug, while administrating 14 consecutive days, was less than 50% due to the drug-related adverse experience.

    Time frame: Up to 26 days

Secondary outcomes

  1. Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State

    AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.

    Time frame: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  2. AUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State

    AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.

    Time frame: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  3. AUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

    AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.

    Time frame: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  4. Maximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

    Time frame: Day 1: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  5. Cmax of Vorinostat After a Single Oral Dose in a Fed State

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

    Time frame: Day 3: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  6. Cmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

    Time frame: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  7. Time to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State

    Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.

    Time frame: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  8. Tmax of Vorinostat After a Single Oral Dose in a Fed State

    Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.

    Time frame: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  9. Tmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

    Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.

    Time frame: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  10. Apparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State

    t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.

    Time frame: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  11. t½ of Vorinostat After a Single Oral Dose in a Fed State

    t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.

    Time frame: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

  12. t½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

    t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.

    Time frame: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

07

Results

Posted May 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneVorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mg
Started3636
Completed2133
Not completed1503
Withdrew: Adverse event0201
Withdrew: Lack of efficacy1302

Outcome measures

PrimaryNumber of Participants Who Experienced One or More Adverse Events

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 4 years
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Adverse Events
ParticipantsVorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mg
Number of Participants Who Experienced One or More Adverse Events4636
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an Adverse Event

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 4 years
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event
ParticipantsVorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mg
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event0101
PrimaryNumber of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1

A DLT was defined as an event considered to be related to study treatment and included: 1) Grade 4 neutropenia refractory to treatments persisting more than 5 days; 2) Grade 3 or more severe neutropenic fever; 3) Grade 3 thrombocytopenia requiring blood transfusions or Grade 4 thrombocytopenia; 4) Grade 4 hemoglobin decrease; 5) Grade 3 or more severe non-hematological toxicities other than anorexia, nausea/vomiting, and fatigue. (For the diarrhea, it was defined as not to use the frequency for the grading. For the alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]), it was defined as the case of over 300 IU/L; 6) Grade 3 or more severe anorexia, nausea/vomiting, and fatigue refractory to treatments; and 7) compliance of the study drug, while administrating 14 consecutive days, was less than 50% due to the drug-related adverse experience.

Time frame:
Up to 26 days
Reported as:
Count of participants · Participants
Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1
ParticipantsVorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mg
Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 10302
SecondaryArea Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State

AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.

Time frame:
Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Geometric mean · μM·hours
Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State
μM·hoursVorinostat 100 mg FASTEDVorinostat 200 mg FASTEDVorinostat 400 mg FASTEDVorinostat 500 mg FASTED
Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State1.20 ± 0.272.31 ± 0.963.96 ± 1.623.47 ± 2.21
SecondaryAUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State

AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.

Time frame:
Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Geometric mean · μM·hours
AUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State
μM·hoursVorinostat 100 mg FEDVorinostat 200 mg FEDVorinostat 400 mg FEDVorinostat 500 mg FED
AUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State0.98 ± 0.072.22 ± 0.894.30 ± 0.375.93 ± 1.78
SecondaryAUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time.

Time frame:
Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Geometric mean · μM·hours
AUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
μM·hoursVorinostat 100 mg Twice-dailyVorinostat 200 mg Twice-dailyVorinostat 400 mg Once-dailyVorinostat 500 mg Once-daily
AUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration1.33 ± 0.232.76 ± 0.855.41 ± 2.186.33 ± 1.53
SecondaryMaximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

Time frame:
Day 1: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Geometric mean · μM
Maximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State
μMVorinostat 100 mg FASTEDVorinostat 200 mg FASTEDVorinostat 400 mg FASTEDVorinostat 500 mg FASTED
Maximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State0.49 ± 0.150.77 ± 0.131.19 ± 0.201.06 ± 0.52
SecondaryCmax of Vorinostat After a Single Oral Dose in a Fed State

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

Time frame:
Day 3: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Geometric mean · μM
Cmax of Vorinostat After a Single Oral Dose in a Fed State
μMVorinostat 100 mg FEDVorinostat 200 mg FEDVorinostat 400 mg FEDVorinostat 500 mg FED
Cmax of Vorinostat After a Single Oral Dose in a Fed State0.21 ± 0.140.59 ± 0.220.93 ± 0.121.35 ± 0.39
SecondaryCmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

Time frame:
Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Geometric mean · μM
Cmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
μMVorinostat 100 mg Twice-dailyVorinostat 200 mg Twice-dailyVorinostat 400 mg Once-dailyVorinostat 500 mg Once-daily
Cmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration0.29 ± 0.250.84 ± 0.560.86 ± 0.611.09 ± 0.30
SecondaryTime to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.

Time frame:
Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Mean · Hours
Time to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State
HoursVorinostat 100 mg FASTEDVorinostat 200 mg FASTEDVorinostat 400 mg FASTEDVorinostat 500 mg FASTED
Time to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State0.84 ± 0.301.59 ± 0.742.49 ± 0.861.91 ± 0.91
SecondaryTmax of Vorinostat After a Single Oral Dose in a Fed State

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.

Time frame:
Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Mean · Hours
Tmax of Vorinostat After a Single Oral Dose in a Fed State
HoursVorinostat 100 mg FEDVorinostat 200 mg FEDVorinostat 400 mg FEDVorinostat 500 mg FED
Tmax of Vorinostat After a Single Oral Dose in a Fed State5.66 ± 3.793.00 ± 0.893.53 ± 2.333.17 ± 1.17
SecondaryTmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.

Time frame:
Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Mean · Hours
Tmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
HoursVorinostat 100 mg Twice-dailyVorinostat 200 mg Twice-dailyVorinostat 400 mg Once-dailyVorinostat 500 mg Once-daily
Tmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration4.66 ± 1.163.30 ± 1.104.34 ± 1.534.61 ± 1.95
SecondaryApparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State

t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.

Time frame:
Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Mean · Hours
Apparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State
HoursVorinostat 100 mg FASTEDVorinostat 200 mg FASTEDVorinostat 400 mg FASTEDVorinostat 500 mg FASTED
Apparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State1.08 ± 0.301.83 ± 0.531.90 ± 0.721.93 ± 0.67
Secondaryt½ of Vorinostat After a Single Oral Dose in a Fed State

t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.

Time frame:
Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Mean · Hours
t½ of Vorinostat After a Single Oral Dose in a Fed State
HoursVorinostat 100 mg FEDVorinostat 200 mg FEDVorinostat 400 mg FEDVorinostat 500 mg FED
t½ of Vorinostat After a Single Oral Dose in a Fed State1.62 ± 0.451.36 ± 0.282.01 ± 1.471.60 ± 0.66
Secondaryt½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate.

Time frame:
Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose
Reported as:
Mean · Hours
t½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration
HoursVorinostat 100 mg Twice-dailyVorinostat 200 mg Twice-dailyVorinostat 400 mg Once-dailyVorinostat 500 mg Once-daily
t½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration1.95 ± 0.541.42 ± 0.501.98 ± 1.561.30 ± 0.41

Adverse events

Collected over Up to approximately 4 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat 100 mg0/3 (0%)0/4 (0%)4/4 (100%)
Vorinostat 200 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Vorinostat 400 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Vorinostat 500 mg0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventVorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mg
Pericardial effusionCardiac disorders0/40/61/30/6
Hepatic function abnormalHepatobiliary disorders0/40/61/30/6
Renal impairmentRenal and urinary disorders0/40/61/30/6
PneumoniaInfections and infestations0/41/60/30/6
Most frequent other events
Showing 10 of 97
Most frequent other events
EventVorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mg
Platelet count decreasedInvestigations1/46/63/34/6
DiarrhoeaGastrointestinal disorders2/45/61/35/6
NauseaGastrointestinal disorders1/45/62/34/6
FatigueGeneral disorders2/45/62/35/6
Neutrophil count decreasedInvestigations2/45/60/31/6
White blood cell count decreasedInvestigations1/45/60/31/6
AnorexiaMetabolism and nutrition disorders1/43/62/35/6
VomitingGastrointestinal disorders1/43/62/31/6
Blood glucose increasedInvestigations1/42/61/34/6
AnaemiaBlood and lymphatic system disorders0/41/61/33/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Vorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mgTotal
Mean59.7 ± 6.760.5 ± 6.349.3 ± 21.557.7 ± 8.357.6 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mgTotal
Female03003
Male333615
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vorinostat 100 mgVorinostat 200 mgVorinostat 400 mgVorinostat 500 mgTotal
American Indian or Alaska Native00000
Asian363618
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Fujiwara Y, Yamamoto N, Yamada Y, Yamada K, Otsuki T, Kanazu S, Iwasa T, Hardwick JS, Tamura T. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci. 2009 Sep;100(9):1728-34. doi: 10.1111/j.1349-7006.2009.01237.x. Epub 2009 May 31. PubMed 19575752 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2005 to primary completion in Aug 2009, 50 months.

Results were first posted in May 2022, 12 years 8 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 50 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2005
First posted
Aug 5, 2005
StartActual
Jun 10, 2005
Primary completionActual
Aug 21, 2009
CompletionActual
Aug 21, 2009
Results first posted
May 2, 2022
Last update
Sep 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00127127
Responsible party
Sponsor
First posted
Aug 5, 2005
Start date
Jun 10, 2005
Primary completion
Aug 21, 2009
Completion
Aug 21, 2009
Results posted
May 2, 2022
Last update
Sep 13, 2022

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion